Search Results
Targeted therapies in newly diagnosed AML: BCL2, FLT3 and IDH inhibitors
Treating AML with BCL-2 inhibitors
Targeted Therapies in AML
Promising targets beyond FLT3 in AML: IDH1/2 & menin
Newly diagnosed AML: Hitting the right target
Combining menin/FLT3/BCL2 inhibition as a treatment approach in FLT3/NPM1 double mutated AML
Clinical Management of Newly Diagnosed AML Patients Receiving a BCL-2 Inhibitor
An overview of the safety profile of FLT3 inhibitors in AML
New Findings and Improved Outcomes in the Treatment of AML
Treatment avenues for patients with R/R FLT3-mutated AML: optimizing FLT3 inhibitors
Acute Myeloid Leukemia: Novel Therapies for Newly Diagnosed Patients - Part 2
Selecting Therapy for Newly Diagnosed AML
